Confirms proposed Phase 3 development pathway and identifies new life cycle management targets for XF-73 Nasal Brighton, United Kingdom – 6 July 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent life threatening infections, recently held a meeting with its Scientific Advisory Board […]
Continued progress on XF-73 partnering discussions Susan Koppy appointed to drive business development activities $2bn XF-73 Nasal market opportunity Brighton, United Kingdom – 29th June 2023: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections, today provides an update on the […]
Brighton, United Kingdom – 25th May 2023: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces, ahead of the AGM, that Neil Clark has decided to step down as Chief Executive Officer to pursue new challenges. Neil will also step down […]
Positive results from testing SPOR-COV in several COVID-19 and influenza research models support potential as prophylactic nasal spray Toxicology studies support safety profile Manufacturing process established Manufacturing and regional licensing agreement signed with HURO Biotech JSC for Vietnam Phase 1 clinical studies completed successfully in Vietnam by HURO Retail product based on SPOR COV technology […]
Destiny Pharma, one of our longstanding clients, featured in the April 2023 edition of MedNous, the specialist medical research journal. Neil Clark, CEO, and Dr Bill Love, Founder and CSO, sat down with Victoria English to discuss the fantastic progress that has been made with Destiny’s two lead assets, XF-73, a nasal gel for the treatment […]
